SG11201912179SA - Targeted non-viral dna insertions - Google Patents

Targeted non-viral dna insertions

Info

Publication number
SG11201912179SA
SG11201912179SA SG11201912179SA SG11201912179SA SG11201912179SA SG 11201912179S A SG11201912179S A SG 11201912179SA SG 11201912179S A SG11201912179S A SG 11201912179SA SG 11201912179S A SG11201912179S A SG 11201912179SA SG 11201912179S A SG11201912179S A SG 11201912179SA
Authority
SG
Singapore
Prior art keywords
viral dna
dna insertions
targeted non
targeted
insertions
Prior art date
Application number
SG11201912179SA
Inventor
Theodore Lee Roth
Alexander Marson
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of SG11201912179SA publication Critical patent/SG11201912179SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201912179SA 2017-06-15 2018-06-15 Targeted non-viral dna insertions SG11201912179SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762520117P 2017-06-15 2017-06-15
US201762552180P 2017-08-30 2017-08-30
PCT/US2018/037919 WO2018232356A1 (en) 2017-06-15 2018-06-15 Targeted non-viral dna insertions

Publications (1)

Publication Number Publication Date
SG11201912179SA true SG11201912179SA (en) 2020-01-30

Family

ID=64659467

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912179SA SG11201912179SA (en) 2017-06-15 2018-06-15 Targeted non-viral dna insertions

Country Status (12)

Country Link
US (4) US20200362355A1 (en)
EP (1) EP3638317A4 (en)
JP (2) JP7275054B2 (en)
KR (1) KR20240027153A (en)
CN (2) CN118599915A (en)
AU (1) AU2018283405A1 (en)
BR (1) BR112019026625A2 (en)
CA (1) CA3067382A1 (en)
IL (1) IL271389A (en)
MX (2) MX2019015188A (en)
SG (1) SG11201912179SA (en)
WO (1) WO2018232356A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004325A (en) 2017-10-27 2020-11-09 Univ California Targeted replacement of endogenous t cell receptors.
CN112654710A (en) 2018-05-16 2021-04-13 辛瑟高公司 Methods and systems for directing RNA design and use
US20230158110A1 (en) * 2018-05-30 2023-05-25 The Regents Of The University Of California Gene editing of monogenic disorders in human hematopoietic stem cells -- correction of x-linked hyper-igm syndrome (xhim)
CN114107292B (en) * 2020-08-27 2024-03-12 阿思科力(苏州)生物科技有限公司 Gene editing system and method for site-directed insertion of exogenous gene
EP4204574A1 (en) * 2020-08-27 2023-07-05 Tmunity Therapeutics Inc. Vector-free process for manufacture of engineered immune cells
CN113046381A (en) * 2021-04-12 2021-06-29 南华大学 Method for separating specific protein-DNA complex in organism, fusion protein and preparation method thereof
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells having co-expressed shrnas and logic gate systems
WO2023220207A2 (en) * 2022-05-10 2023-11-16 Editas Medicine, Inc. Genome editing of cells
TW202417626A (en) 2022-09-13 2024-05-01 美商亞森諾生物科學公司 Immune cells having co-expressed tgfbr shrnas
WO2024059824A2 (en) 2022-09-16 2024-03-21 Arsenal Biosciences, Inc. Immune cells with combination gene perturbations
WO2024182219A1 (en) 2023-02-27 2024-09-06 Adaptive Biotechnologies Corp. Therapeutic t cell receptors targeting kras g12d
US20240342284A1 (en) 2023-03-03 2024-10-17 Arsenal Biosciences, Inc. Systems targeting psma and ca9
WO2024192100A1 (en) 2023-03-13 2024-09-19 Arsenal Biosciences, Inc. Synthetic pathway activators

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US20020064802A1 (en) 2000-04-28 2002-05-30 Eva Raschke Methods for binding an exogenous molecule to cellular chromatin
US20050136040A1 (en) 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
GB0124391D0 (en) 2001-10-11 2001-11-28 Gene Expression Technologies L Control of gene expression
US20030232410A1 (en) 2002-03-21 2003-12-18 Monika Liljedahl Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
ITMI20030821A1 (en) 2003-04-18 2004-10-19 Internat Ct For Genetic En Gineering And CHEMICAL POLYPEPTIDES AND THEIR USE.
KR20060054196A (en) 2003-06-10 2006-05-22 주식회사 툴젠 Transducible dna-binding protein
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20070254291A1 (en) 2004-06-14 2007-11-01 Xiaoxia Cui Gene Targeting in Eukaryotic Cells by Group II Intron Ribonucleoprotein Particles
US10022457B2 (en) 2005-08-05 2018-07-17 Gholam A. Peyman Methods to regulate polarization and enhance function of cells
EP3284833B1 (en) 2005-08-26 2021-12-01 DuPont Nutrition Biosciences ApS Use of crispr associated genes (cas)
ZA200900787B (en) 2006-08-11 2010-05-26 Dow Agrosciences Llc Zinc finger nuclease-mediated homologous recombination
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
EP2424877A4 (en) 2009-04-28 2013-01-02 Harvard College Supercharged proteins for cell penetration
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP2013513389A (en) 2009-12-10 2013-04-22 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ DNA modification mediated by TAL effectors
US9567573B2 (en) 2010-04-26 2017-02-14 Sangamo Biosciences, Inc. Genome editing of a Rosa locus using nucleases
US8876458B2 (en) 2011-01-25 2014-11-04 United Technologies Corporation Blade outer air seal assembly and support
WO2013074916A1 (en) 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US20130236504A1 (en) 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
HUE038850T2 (en) 2012-05-25 2018-11-28 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
CN110066775B (en) 2012-10-23 2024-03-19 基因工具股份有限公司 Composition for cleaving target DNA and use thereof
KR101844123B1 (en) 2012-12-06 2018-04-02 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-based genome modification and regulation
AU2013359262C1 (en) 2012-12-12 2021-05-13 Massachusetts Institute Of Technology CRISPR-Cas component systems, methods and compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
KR20140101203A (en) 2013-02-08 2014-08-19 이정민 Auto buffing machine
EP3467125B1 (en) 2013-03-15 2023-08-30 The General Hospital Corporation Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
US9937207B2 (en) 2013-03-21 2018-04-10 Sangamo Therapeutics, Inc. Targeted disruption of T cell receptor genes using talens
WO2014161821A1 (en) 2013-04-02 2014-10-09 Bayer Cropscience Nv Targeted genome engineering in eukaryotes
AU2014273490B2 (en) 2013-05-29 2019-05-09 Cellectis Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease system
ES2883131T3 (en) 2013-05-29 2021-12-07 Cellectis Methods for modifying T cells for immunotherapy using the RNA-guided CAS nuclease system
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US10822606B2 (en) 2013-09-27 2020-11-03 The Regents Of The University Of California Optimized small guide RNAs and methods of use
ES2881473T3 (en) 2013-10-17 2021-11-29 Sangamo Therapeutics Inc Delivery methods and compositions for nuclease-mediated genetic engineering of the genome
CA2930590C (en) 2013-11-15 2021-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Engineering neural stem cells using homologous recombination
US10787684B2 (en) * 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
MX2016007328A (en) 2013-12-12 2017-07-19 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for genome editing.
EP3080271B1 (en) 2013-12-12 2020-02-12 The Broad Institute, Inc. Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
MX2016007327A (en) 2013-12-12 2017-03-06 Broad Inst Inc Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components.
CA2932472A1 (en) * 2013-12-12 2015-06-18 Massachusetts Institute Of Technology Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
WO2015086795A1 (en) 2013-12-13 2015-06-18 Cellectis Cas9 nuclease platform for microalgae genome engineering
CN105940110A (en) 2014-01-31 2016-09-14 菲克特生物科学股份有限公司 Methods and products for nucleic acid production and delivery
WO2015115903A1 (en) 2014-02-03 2015-08-06 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Site-specific dna break-induced genome editing using engineered nucleases
KR102595473B1 (en) 2014-04-18 2023-10-30 에디타스 메디신, 인코포레이티드 Crispr-cas-related methods, compositions and components for cancer immunotherapy
EP3194578B1 (en) 2014-08-06 2021-03-10 College of Medicine Pochon Cha University Industry-Academic Cooperation Foundation Immune-compatible cells created by nuclease-mediated editing of genes encoding hla
EP3188763B1 (en) 2014-09-02 2020-05-13 The Regents of The University of California Methods and compositions for rna-directed target dna modification
WO2016049251A1 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
CN113930455A (en) 2014-10-09 2022-01-14 生命技术公司 CRISPR oligonucleotides and gene clips
ES2983094T3 (en) 2014-10-31 2024-10-21 Univ Pennsylvania Alteration of gene expression in CAR-T cells and their uses
WO2016097751A1 (en) 2014-12-18 2016-06-23 The University Of Bath Method of cas9 mediated genome engineering
CN114642735A (en) 2015-01-21 2022-06-21 菲泽尔克斯公司 Methods, compositions and systems for delivering therapeutic and diagnostic agents into cells
EP3250693B2 (en) * 2015-01-30 2023-12-20 The Regents of The University of California Protein delivery in primary hematopoietic cells
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
CN107614012A (en) 2015-04-24 2018-01-19 加利福尼亚大学董事会 Using the cell detection of engineering, monitoring or treatment disease or the system of the patient's condition and preparation and use their method
MX2017015239A (en) 2015-05-29 2018-02-19 Juno Therapeutics Inc Composition and methods for regulating inhibitory interactions in genetically engineered cells.
AU2016278982A1 (en) 2015-06-17 2018-01-18 The Uab Research Foundation CRISPR/Cas9 complex for genomic editing
WO2016205680A1 (en) * 2015-06-17 2016-12-22 The Uab Research Foundation Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
US20170000743A1 (en) 2015-07-02 2017-01-05 Vindico NanoBio Technology Inc. Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
US10450585B2 (en) 2015-07-13 2019-10-22 Sangamo Therapeutics, Inc. Delivery methods and compositions for nuclease-mediated genome engineering
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US20180243446A1 (en) 2015-09-01 2018-08-30 The Hospital For Sick Children Method and compositions for removing duplicated copy number variaions (cnvs) for genetic disorders and related uses
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
WO2017058751A1 (en) 2015-09-28 2017-04-06 North Carolina State University Methods and compositions for sequence specific antimicrobials
CN117070468A (en) 2015-10-05 2023-11-17 精密生物科学公司 Genetically modified cells comprising modified human T cell receptor alpha constant region genes
WO2017070169A1 (en) 2015-10-19 2017-04-27 The Methodist Hospital Crispr-cas9 delivery to hard-to-transfect cells via membrane deformation
WO2017070056A1 (en) 2015-10-20 2017-04-27 10X Genomics, Inc. Methods and systems for high throughput single cell genetic manipulation
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
AU2016349504B2 (en) 2015-11-04 2023-02-09 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
JP2019500899A (en) 2015-11-23 2019-01-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Cellular RNA tracking and manipulation through nuclear delivery of CRISPR / Cas9
UA126373C2 (en) * 2015-12-04 2022-09-28 Новартіс Аг Compositions and methods for immunooncology
JP7128741B2 (en) 2015-12-18 2022-08-31 サンガモ セラピューティクス， インコーポレイテッド Targeted disruption of T-cell receptors
WO2017115128A2 (en) 2015-12-30 2017-07-06 Avectas Limited Vector-free delivery of gene editing proteins and compositions to cells and tissues
MX2018010924A (en) 2016-03-11 2019-02-13 Bluebird Bio Inc Genome edited immune effector cells.
JP2019510503A (en) 2016-04-07 2019-04-18 ブルーバード バイオ， インコーポレイテッド Chimeric antigen receptor T cell composition
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
AU2017250295B2 (en) 2016-04-14 2022-08-25 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
ES2933961T3 (en) 2016-04-15 2023-02-15 Memorial Sloan Kettering Cancer Center Transgenic T Cells and Chimeric Antigen Receptor T Cell Compositions and Related Methods
US11248216B2 (en) 2016-04-25 2022-02-15 The Regents Of The University Of California Methods and compositions for genomic editing
JP7148494B2 (en) * 2016-04-25 2022-10-05 ウニベルシテート バーゼル Allele editing and its applications
EP3448990B1 (en) 2016-04-29 2021-06-09 BASF Plant Science Company GmbH Methods for modification of target nucleic acids using a fusion molecule of guide and donor rna, fusion rna molecule and vector systems encoding the fusion rna molecule
US20190136224A1 (en) 2016-05-31 2019-05-09 Massachusetts Institute Of Technology Hydrodynamically Controlled Electric Fields for High Throughput Transformation & High Throughput Parallel Transformation Platform
ES2982085T3 (en) 2016-06-20 2024-10-14 Octapharma Ag Means and methods for modifying multiple alleles
US20200283743A1 (en) 2016-08-17 2020-09-10 The Broad Institute, Inc. Novel crispr enzymes and systems
US11999931B2 (en) 2016-08-20 2024-06-04 The Regents Of The University Of California High-throughput system and method for the temporary permeabilization of cells
WO2018068135A1 (en) 2016-10-12 2018-04-19 Feldan Bio Inc. Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same
WO2018073391A1 (en) 2016-10-19 2018-04-26 Cellectis Targeted gene insertion for improved immune cells therapy
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3541937A4 (en) 2016-11-18 2020-06-24 Christopher Bradley Massively multiplexed homologous template repair for whole-genome replacement
AU2017378431A1 (en) 2016-12-14 2019-06-20 Ligandal, Inc. Compositions and methods for nucleic acid and/or protein payload delivery
EP3562594A4 (en) 2016-12-30 2020-09-09 The Regents of University of California Methods for selection and generation of genome edited t cells
MX2020004325A (en) 2017-10-27 2020-11-09 Univ California Targeted replacement of endogenous t cell receptors.
CN117904055A (en) 2017-10-30 2024-04-19 派克特制药公司 Primary cell gene editing

Also Published As

Publication number Publication date
CN111344020A (en) 2020-06-26
JP2020524998A (en) 2020-08-27
EP3638317A1 (en) 2020-04-22
BR112019026625A2 (en) 2020-06-30
MX2024006956A (en) 2024-06-24
IL271389A (en) 2020-01-30
KR20240027153A (en) 2024-02-29
MX2019015188A (en) 2020-08-03
WO2018232356A1 (en) 2018-12-20
US20210388362A1 (en) 2021-12-16
CN118599915A (en) 2024-09-06
EP3638317A4 (en) 2021-03-17
US20200362355A1 (en) 2020-11-19
AU2018283405A1 (en) 2020-01-16
CA3067382A1 (en) 2018-12-20
US20220064653A1 (en) 2022-03-03
US11814624B2 (en) 2023-11-14
JP7275054B2 (en) 2023-05-17
JP2023100828A (en) 2023-07-19
KR20200018645A (en) 2020-02-19
US20240117360A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
IL271389A (en) Targeted non-viral dna insertions
IL261327A (en) Trans-replicating rna
IL284577A (en) Gene therapy
HK1252755B (en) Engineered nucleic-acid targeting nucleic acids
GB2557088B (en) Blower
EP3370731A4 (en) Nucleotide analogues
EP3328873A4 (en) Targeted oligonucleotides
EP3512535A4 (en) Targeted enhanced dna demethylation
HUE056570T2 (en) Gene therapy
EP3619311C0 (en) Dna assembly
EP3312431A4 (en) Blower
IL257500A (en) Modified cullin1 gene
GB201517241D0 (en) DNA modification
SG11202004757RA (en) Dna polymerases
GB201701968D0 (en) Gene therapy
IL263085A (en) Gene therapy
EP3299636A4 (en) Blower
GB201513151D0 (en) Functional gene replacement therapy
GB201713546D0 (en) DNA assembly
GB201707049D0 (en) DNA Assembly
GB201704634D0 (en) Gene therapy
GB201616821D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
SG10201912076UA (en) Gene therapy composition